Reports have indicated that (1) high expression of cyclin D1 after TUR treatment shortens the time to recurrence in humans [38], (2) COX inhibitors may have a suppressive effect on bladder cancer [39], and (3) patients treated with antiandrogen therapy have a low rate of bladder cancer recurrence [40,41]. Here, CCND1 is linked to urinary bladder carcinoma.